Tanabe Pharma Corporation: all 185 studies

Page 2 of 2. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• A Study of MT-2111 in Patients With Relapsed/Refractory DLBCLActive, not recruitingNCT05658562Phase 1/2
• A Clinical Pharmacology Study of MT-3921 in Healthy Adult MalesCompletedNCT05396235Phase 1
• Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy SubjectsCompletedNCT05241535Phase 1
• A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)CompletedNCT05240612Phase 1
• A Study of MT-0551 in Patients With Systemic SclerosisActive, not recruitingNCT05198557Phase 3
• Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral NeuropathyCompletedNCT05123196Phase 2
• Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 VaccineWithdrawnNCT05040789Phase 3
• Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Active, not recruitingNCT05005975Phase 3
• Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy SubjectsCompletedNCT04793295Phase 1
• Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord InjuryCompletedNCT04683848Phase 2
• PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal FunctionCompletedNCT04656795Phase 1
• Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in AdultsActive, not recruitingNCT04636697Phase 2/3
• Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.CompletedNCT04450004Phase 1
• Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic FunctionCompletedNCT04116476Phase 1
• Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord InjuryCompletedNCT04096950Phase 1
• Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor FluctuationsActive, not recruitingNCT04006210Phase 3
• Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump InhibitorCompletedNCT03688022Phase 1
• A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis PatientsCompletedNCT03570957Phase 1
• Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and InfantsCompletedNCT03507738Phase 1
• Mass Balance Study With MT-7117CompletedNCT03503266Phase 1
• Definitive QT Study With MT-8554CompletedNCT03471130Phase 1
• A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral SuspensionWithdrawnNCT03462043Phase 3
• Mass Balance Study With MT-8554CompletedNCT03381404Phase 1
• Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral NeuropathyCompletedNCT03172598Phase 2
• A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy VolunteersCompletedNCT03156738Phase 1
• A Clinical Study to See How the Study Drug MT-4129 is Taken up by the Body in Healthy VolunteersCompletedNCT02953132Phase 1
• Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)CompletedNCT02923154Phase 2
• Mass Balance Study of MT-3995CompletedNCT02900235Phase 1
• A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy SubjectsCompletedNCT02834442Phase 1
• Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly AdultsCompletedNCT02831751Phase 2
• A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor SymptomsCompletedNCT02803268Phase 1
• A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor FluctuationsWithdrawnNCT02782481Phase 3
• Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy AdultsCompletedNCT02768805Phase 2
• An Extended Treatment Study of MT-3995 in Patients With Diabetic NephropathyCompletedNCT02676401Phase 2
• A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy SubjectsCompletedNCT02675309Phase 1
• A Sequential Two-Part, Open-Label Study in Healthy Male and Female SubjectsCompletedNCT02604914Phase 1
• A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy SubjectsCompletedNCT02536209Phase 1
• Drug Interaction Study of Warfarin and MT-3995CompletedNCT02531568Phase 1
• Efficacy and Safety of MT-3995 in Patients With Diabetic NephropathyCompletedNCT02517320Phase 2
• A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)CompletedNCT02486432Phase 1
• A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy SubjectsCompletedNCT02429102Phase 1
• Extension Study of MT-1303 in Subjects With Crohn's DiseaseCompletedNCT02389790Phase 2
• Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's DiseaseCompletedNCT02378688Phase 2
• Safety Study of MT-4666 in Subjects With Alzheimer's DiseaseTerminatedNCT02327182Phase 3
• Comparative Oral Bioavailability Study of MT-1303CompletedNCT02310048Phase 1
• Exploratory Study of MT-1303 in Systemic Lupus Erythematosus PatientsCompletedNCT02307643Phase 1
• Mass Balance Study of MT-1303CompletedNCT02293967Phase 1
• Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly PopulationCompletedNCT02236052Phase 2
• Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in AdultsCompletedNCT02233816Phase 2
• Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic NephropathyCompletedNCT02205372Phase 1/2
• A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303CompletedNCT02193217Phase 1
• Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's DiseaseCompletedNCT02148185Phase 1
• A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease PatientsCompletedNCT02096601Phase 1
• Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.CompletedNCT02022163Phase 1
• Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in AdultsCompletedNCT01991587Phase 1/2
• Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.CompletedNCT01991561Phase 2
• Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT01987843Phase 2
• Extension Study of MT-1303CompletedNCT01890655Phase 2
• Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic NephropathyCompletedNCT01889277Phase 1/2
• Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy SubjectsCompletedNCT01879020Phase 1
• Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy SubjectsCompletedNCT01878474Phase 1
• Safety and Tolerability Study of MCI-196TerminatedNCT01818687Phase 3
• Long-term Extension Study of MCI-196TerminatedNCT01814917Phase 3
• Dose-finding Study of MCI-196TerminatedNCT01814904Phase 3
• Clinical Pharmacology Study of MP-424CompletedNCT01766167Phase 1
• Safety and Efficacy of MT-4666CompletedNCT01764243Phase 2
• A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFRCompletedNCT01756716Phase 2
• A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With AlbuminuriaCompletedNCT01756703Phase 2
• Dose-finding Study of MT-1303CompletedNCT01742052Phase 2
• A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) PatientsCompletedNCT01725802Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel DiseaseCompletedNCT01666327Phase 1
• Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy VolunteersCompletedNCT01486628Phase 1
• Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in AdultsCompletedNCT01302990Phase 1
• Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza VaccineCompletedNCT01244867Phase 2
• A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease PatientsCompletedNCT01229332Phase 1/2
• A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)CompletedNCT01174355Phase 1/2
• Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611CompletedNCT01103011Phase 1
• Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy AdultsCompletedNCT00984945Phase 1
• A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With HyperphosphatemiaTerminatedNCT00451295Phase 3
• Safety and Efficacy of MCC-257 in the Treatment of Diabetic PolyneuropathyCompletedNCT00307749Phase 2
• Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology StudyCompletedNCT00147303Phase 3
• Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)CompletedNCT00129805Phase 3
• MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction PatientsCompletedNCT00078013Phase 2
• Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial DiseaseCompletedNCT00059657Phase 3
• Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial DiseaseTerminatedNCT00059644Phase 3

← Tanabe Pharma Corporation overview and focus areas